RxDoctor Payments Data

Aleah Gibson, MD

Family Medicine · Greendale, INNPI 1780792903

Payments from drug & device makers

$4,736in general payments, 2019–2025

Across 283 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$680
  • Novo Nordisk$484
  • Pfizer$391
  • Amgen$337
  • Lilly USA, LLC$250
  • Exact Sciences$247
  • plus $2K from 32 others

What the payments were for

  • Food & beverage$4,728100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,736 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$61,587
Medicare patients
160
Services billed
1,086

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide124$205,111
MounjaroTirzepatide38$70,046
EliquisApixaban64$51,579
TrulicityDulaglutide44$46,005
JardianceEmpagliflozin24$35,220
XareltoRivaroxaban27$29,550
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$28,460
LinzessLinaclotide31$27,797
FarxigaDapagliflozin Propanediol20$26,102
Tresiba Flextouch U-200Insulin Degludec16$21,969
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$19,447
Aimovig AutoinjectorErenumab-Aooe16$17,687
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$14,264
MyrbetriqMirabegron22$13,580
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen300$9,430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$484$205,111124 claims
Lilly USA, LLCMounjaro, Trulicity$250$116,05182 claims
PfizerEliquis$391$51,57964 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$231$46,76653 claims
Boehringer IngelheimJardiance$35$35,22024 claims
Johnson & JohnsonXarelto$31$29,55027 claims
AbbVieLinzess$680$27,79731 claims
GSKTrelegy Ellipta$231$19,44725 claims
Astellas Pharma US IncMyrbetriq$18$13,58022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Greendale

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →